Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Moss – page 2

130 clinical trials in Moss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Moss at a glance
130
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

130 trials in Moss

Open in trial search

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Phase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:Odense University Hospital

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Boehringer Ingelheim International GmbH

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Major depression+1

Recruiting

A study on ketamine maintenance treatment for patients with treatment-resistant major depression disorder

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ketamine Hydrochloride
  • Sponsor:Ostfold Hospital Trust

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Region Midtjylland

Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Moss

What the registry says about research in the country

01 Rheumatology & Immunology

Clinical research focusing on giant cell arteritis (GCA), exploring innovative therapeutic approaches for this rare inflammatory blood vessel condition. The trials aim to evaluate new treatment combinations that could improve patient outcomes while optimizing glucocorticoid therapy regimens.

  • Inflammatory Vascular Disorders
  • Autoimmune Disease Management
  • Targeted Immunotherapy

These investigations are designed to assess the effectiveness of combining novel biological treatments with traditional steroid therapies, potentially offering new hope for patients managing chronic inflammatory conditions.

02 Therapeutic Innovation

Advanced studies evaluating combination therapy approaches that integrate biological agents with standardized glucocorticoid tapering protocols. This research aims to establish more effective treatment strategies while potentially reducing long-term steroid exposure.

  • Treatment Optimization
  • Steroid-Sparing Strategies
  • Long-term Disease Management

The research focuses on developing sustained remission protocols that could revolutionize the standard of care for inflammatory vascular conditions.

03 Clinical Outcomes

Comprehensive evaluation of treatment efficacy and safety in vascular inflammation, with particular attention to sustained disease remission. The research examines both immediate therapeutic responses and long-term outcomes in patients with inflammatory arterial disease.

  • Remission Assessment
  • Safety Monitoring
  • Quality of Life Impacts

These trials are designed to provide crucial data on the effectiveness of new therapeutic approaches in achieving and maintaining disease control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.